Cartesian Therapeutics Inc
RNAC
查看详细走势图
6.490USD
+0.210+3.34%
收盘 02/06, 16:00（美东）报价延迟15分钟
168.76M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+3.34%
5天
-4.98%
1月
-7.81%
6月
-42.46%
今年开始到现在
-9.99%
1年
-65.50%
查看详细走势图
TradingKey Cartesian Therapeutics Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
Cartesian Therapeutics Inc当前公司基本面数据相对稳定，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名177/392位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价35.57。中期看，股价处于下降通道。近一个月，市场表现非常差，基本面和技术面综合得分也较低。目前股价在压力位和支撑位之间，可以做区间波段操作。
Cartesian Therapeutics Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看好
Cartesian Therapeutics Inc亮点
亮点风险
Cartesian Therapeutics, Inc. is a clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. It leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function. The Company’s lead asset, Descartes-08, is a chimeric antigen receptor T-cell therapy (CAR-T) entering Phase 3 clinical development for patients with generalized myasthenia gravis and Phase 2 development for systemic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-B-cell maturation antigen (BCMA) CAR-T being evaluated in a Phase 1 trial in patients with multiple myeloma. Descartes-08 is an autologous chimeric antigen receptor T-cell therapy product targeting B-cell maturation antigen in clinical development for generalized myasthenia gravis and systemic lupus erythematosus.
业绩增长期
公司处于发展阶段，最新年度总收入38.91M美元
估值合理
公司最新PE估值-4.91，处于3年历史合理位
机构减仓
最新机构持股6.46M股，环比减少15.21%
先锋集团持仓
明星投资者先锋集团持仓，最新持仓市值541.23K
分析师目标
根据
9
位分析师
买入
评级
35.571
目标均价
+466.42%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Cartesian Therapeutics Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Cartesian Therapeutics Inc简介
Cartesian Therapeutics, Inc. is a clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. It leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function. The Company’s lead asset, Descartes-08, is a chimeric antigen receptor T-cell therapy (CAR-T) entering Phase 3 clinical development for patients with generalized myasthenia gravis and Phase 2 development for systemic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-B-cell maturation antigen (BCMA) CAR-T being evaluated in a Phase 1 trial in patients with multiple myeloma. Descartes-08 is an autologous chimeric antigen receptor T-cell therapy product targeting B-cell maturation antigen in clinical development for generalized myasthenia gravis and systemic lupus erythematosus.
公司代码RNAC
公司Cartesian Therapeutics Inc
CEOBrunn (Carsten)
网址https://www.cartesiantherapeutics.com/
相关品种
